EGFR and non-small cell lung carcinoma: Age (<75 vs. > 74 years, p = 0.006), gender (female vs. male, p = 0.0002), smoking habit index (no-plus-light vs. heavy smokers, p = 0.003), performance score = PS (≤1 vs. ≥ 2, p < 0.0001), TNM substage (IVA vs. IVB, p < 0.0001), pathological type (adenocarcinomas vs. all other NSCLC subtypes, p < 0.0001), sum of TNM + PS + pathology (p < 0.0001), EGFR mutations (no vs. yes, p = 0.04), the number of platinum-based-chemotherapy (PBT) cycles (p < 0.0001), and TKI-TT (p = 0.007).